SUVEN PHARMACEUTICALS: TO PRESENT MASUPIRDINE PHASE-3
**SUVEN PHARMACEUTICALS: TO PRESENT MASUPIRDINE PHASE-3 AND TENACLIDINE PHASE-1 DATA AT CTAD 2026** SUVEN - **Masupirdine – Phase 3:** To present baseline demographics and clinical characteristics from its global Phase 3 study evaluating Masupirdine (SUVN-502) for agitation in Alzheimer's dementia at CTAD 2026 in Boston. - **Clinical Progress:** Phase 3 study enrolment has been completed, with baseline characteristics consistent with published studies and no major safety concerns identified to date. - **Upcoming Milestone:** Masupirdine Phase 3 topline results are scheduled for Q2 FY27. - **Tenaclidine – Phase 1:** To present SAD/MAD study data for Tenaclidine (SUVN-I6107) in healthy subjects, covering safety, tolerability, pharmacokinetics and food, age and gender effects. - **Further Development:** The company is encouraged by Tenaclidine's clinical findings and plans to advance the asset into patient studies. **Impact: Positive** – Progress across two CNS pipeline assets strengthens Suven's clinical development portfolio. However, the key value inflection for Masupirdine remains its Phase 3 topline results expected in Q2 2027.



















